media – Page 68 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

FCE Pharma

Organiser：Nuremberg Exhibition Co. LTD Time：June 10th – 12th, 2025 address：Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1,5 São Paulo – SP Exhibition hall：São Paulo Expo Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, Hormones, Antipyretics and Analgesics, Medicines for Digestive System, Anti-infective Drugs, Antiparasitic Drugs, Cardiovascular Drugs, Intermediates Medical Devices: Pharmaceutical Packaging Materials, PVC/PVDC Laminates, PVC Rigid Sheets, PS Sheets, Packaging Anti-counterfeiting Technology Information, Labeling and Sleeve Labeling Technology, LabelFilling Machines, Packaging Container Forming, Filling, and Sealing Machines, Wrapping Machines, Paper Film Packaging Machinery, etc. Others: Large Infusion Equipment Production Lines, Dryers, Water Treatment Equipment, Refrigeration Compressors, Distillation Equipment, Sterilization Equipment, Tablet Presses, Coating Machines, Plastic Processing Equipment, Crystallization Equipment, etc. About FCE Pharma： FCE Pharma – the International Pharmaceutical Ingredients and Pharmaceutical Exhibition in São Paulo, Brazil, is the premier pharmaceutical technology exhibition in South America. It plays a pivotal role in the development of the pharmaceutical ...
- Source: drugdu
- 362
- August 9, 2024
China moves to advance high-quality development of service consumption

China will work to further develop consumer services to support high-quality economic development and meet people’s demand for personalized, diversified and quality services, according to a guideline made public Saturday. The guideline, issued by the State Council, set out 20 key tasks, including tapping the potential of consumption in sectors such as hospitality, domestic services, elderly care, childcare, entertainment, tourism, sports, education and training. It also pledged to foster new types of consumption like digital, green and health services, create new consumption scenarios, relax market access, strengthen regulation and provide more policy support for service consumption. China will continue to open up sectors such as telecommunications, education, elderly care and medical care, and ensure the implementation of opening-up measures in areas like technology services and tourism, according to the document. The country will also optimize entry policies and consumption environments, speed up the resumption of flights, provide diversified payment services, ...
- Source: drugdu
- 101
- August 9, 2024
Chinese CAR-T Pioneer Legend Biotech in Profile

Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA for second-line treatment of multiple myeloma. From its original roots in China to its first FDA approval in 2022, the company has remained uniquely focused on CAR-T cells targeting the BCMA protein. Humble Beginnings and a Breakthrough Approval Back in 2014, a team of Chinese scientists began investigating cell therapies for cancer under the banner of the “Legend Project,” operating in what the company calls “a room the size of a freight elevator.” After making the decision to focus its research solely on chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein in 2015, Legend began conducting its first clinical trials in 2016. The pioneering biotech landed its first major vote of confidence from the global life sciences community in 2017, ...
- Source: drugdu
- 75
- August 9, 2024
Janssen’s psoriasis drug shows promise for childhood diabetes

A new study led by researchers from Cardiff University, King’s College London (KCL), Swansea University and the University of Calgary has revealed that Janssen’s psoriasis drug, Stelara (ustekinumab), shows promise in treating childhood diabetes. Published in Nature Medicine and funded by a Medical Research Council and National Institute for Health and Care Research partnership, the study found that Stelara was more effective in treating the early stages of type 1 diabetes (T1D) in children and adolescents. Accounting for approximately 10% of diabetes cases in the UK, T1D occurs when the pancreas does not produce insulin or makes very little insulin. Since 2009, the immunotherapy Stelara has been used to treat psoriasis, a skin condition characterised by flaky patches of skin that affects around 60 million people globally, as well as other immune conditions, including psoriatic arthritis, severe Crohn’s disease and severe ulcerative colitis. In the study, researchers tested Stelara in ...
- Source: drugdu
- 70
- August 9, 2024
MRC and MND Association award £3.9m to KCL and UCL for ALS/FTD research

The Medical Research Council and the Motor Neurone Disease (MND) Association have awarded researchers from King’s College London (KCL) and University College London (UCL) £3.9m to investigate an early disease pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The team aims to explore and systematically investigate the axonal dysfunction in neurodegeneration and design therapeutic strategies to address the disease at an early stage. Axonal dysfunction occurs when there is a complete degeneration of axons – parts of the neurons that allow them to carry signals and transmit information to other cells. These results are seen in neurodegenerative diseases such as ALS and FTD. ALS is a fatal type of MND that causes progressive degeneration of nerve cells in the spinal cord and brain, while FTD is the result of damage to neurons in the frontal and temporal lobes of the brain. Combined, these conditions are estimated to affect ...
- Source: drugdu
- 76
- August 9, 2024
【EXPERT Q&A】FDA Approves new colorectal cancer Screening method, How will it be implemented?

Drugdu.com expert’s response: The Food and Drug Administration (FDA) in the United States has approved a novel screening method for colorectal cancer (CRC) known as Shield Blood Test, with the following specific implementation details: Ⅰ. Target Population The Shield Blood Test is approved for use in screening the average-risk population aged 45 or older for colorectal cancer. This is based on the high incidence of CRC within this age range and the importance of screening for early detection and treatment. Ⅱ. Detection Principle The Shield Blood Test is a qualitative in vitro diagnostic test designed to detect CRC-derived mutations in cell-free DNA (cfDNA) collected from blood samples using the Guardant Blood Collection Kit. This test assesses an individual’s risk of developing cancer by identifying specific biomarkers associated with CRC in the blood. III. Testing Process Sample Collection: Blood samples are collected from patients by physicians or other healthcare professionals using ...
- Source: drugdu
- 66
- August 9, 2024
Highly Accurate Blood Test Detects Pancreatic Cancer Early in At-Risk Patients

Pancreatic ductal adenocarcinoma (PDAC), the most prevalent type of pancreatic cancer, is highly lethal but can potentially be cured with surgery and modern treatments. There is a pressing need for a simple, quick, and accessible blood test to diagnose pancreatic cancer early in at-risk individuals. Now, a new pancreatic cancer detection test offers significantly improved accuracy, fulfilling this need and potentially boosting survival rates for these patients. Immunovia AB (Lund, Sweden) has reported enhanced outcomes for its next-generation test aimed at detecting early-stage PDAC in high-risk individuals. In April 2024, the company shared positive outcomes from the preliminary model-development study of its innovative pancreatic cancer detection test. This study incorporated 624 patient samples collected from 13 distinct clinical sites, including 129 samples from patients diagnosed with stage 1 or 2 PDAC and 495 control samples, primarily from individuals at elevated risk for hereditary and/or familial pancreatic cancer. The control group ...
- Source: drugdu
- 64
- August 8, 2024
Novel Cervical Cancer Screening Method to Reduce Need for Invasive Procedures

Cervical cancer remains a significant global health issue, with about 500,000 new cases identified annually. The incidence of cervical intraepithelial neoplasia (CIN), or precursor lesions to cervical cancer, is even more common, occurring 20 times as frequently. Timely detection of these conditions is crucial for effective treatment and improved patient outcomes, underscoring the importance of advancing screening techniques for CIN and cervical cancer. The primary methods currently employed are the human papillomavirus (HPV) test and cytology examination. While cytology is a longstanding method with widespread use, its sensitivity for detecting CIN is relatively low. Conversely, while HPV tests are highly sensitive, they often lack specificity since not all HPV infections lead to cervical lesions. This underscores the pressing need for more refined diagnostic approaches. Against this backdrop, researchers at Fujita Health University (Aichi, Japan) have been exploring biomarkers that could facilitate the early detection of cervical cancer. Their latest findings, ...
- Source: drugdu
- 92
- August 8, 2024
Kerendia Demonstrates Significant Efficacy Treating Heart Failure with Left Ventricular Ejection Fraction of 40% or More

By Don Tracy, Associate Editor The FINEARTS-HF study, which compared Kerendia to a placebo when added to standard therapy, met its primary endpoint by reducing cardiovascular death and total heart failure events. Results from the Phase III FINEARTS-HF study found that Bayer’s Kerendia (finerenone) demonstrated significant efficacy in treating heart failure patients with a left ventricular ejection fraction (LVEF) of 40% or greater. According to the company, the study met its primary endpoint by significantly reducing the composite measure of cardiovascular death and total heart failure events, including both hospitalizations and urgent visits for heart failure.1 “We are very excited by the positive results from the FINEARTS-HF study,” said Christian Rommel, PhD, head of Research and Development, Bayer’s Pharmaceuticals Division. “With limited options currently available for patients with this common form of heart failure with a mildly reduced or preserved ejection fraction, this news is hugely important for patients and ...
- Source: drugdu
- 66
- August 8, 2024
Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer

The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business. By Frank Vinluan A Servier Pharmaceuticals drug designed to penetrate the brain to hit its targets is now FDA approved for treating two rare types of brain cancer. The FDA approval announced Tuesday covers the treatment of adults and adolescents 12 and older who have Grade 2 astrocytoma or oligodendroglioma. The drug, vorasidenib, may be prescribed after surgery, as long as the cancers have mutations to the IDH1 or IDH2 enzymes the once-daily pill is designed to inhibit. The FDA said this regulatory decision marks the agency’s first for a systemic therapy for these cancers driven by either the IDH1 or IDH2 mutations. France-based Servier, which has its U.S. headquarters in Boston, will commercialize ...
- Source: drugdu
- 75
- August 8, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.